FDA Approves Kisqali Regimen for HR+/HER2- Early Breast Cancer
The FDA has approved Kisqali plus an aromatase inhibitor for patients with HR-positive, HER2-negative early breast cancer. The Food and ...
Tag: HR positive
Chemotherapy De-Escalation Associated With Excellent HR+/HER2+ Breast Cancer Survival
Patients with hormone receptor-positive (HR+)/HER2+ early breast cancer who were treated with neoadjuvant (presurgical) endocrine therapy or chemotherapy plus Herceptin ...
Enhertu Maintains Quality of Life in Metastatic Breast Cancer Subgroup
Patients with HR-positive, HER2-low or -ultralow metastatic breast cancer (MBC) treated with Enhertu (trastuzumab deruxtecan) had a reduced deterioration in ...